Modeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity
The model predicted that all doses of tirzepatide represent cost-effective alternatives to LSM for management of overweight and obesity at a willingness-to-pay threshold of $150,000 per QALY.
Authors
- Meredith M. Hoog (ORCID: https://orcid.org/0009-0000-1954-847X)
- Lisa M. Neff (ORCID: https://orcid.org/0000-0002-3006-6057)
- Donna Mojdami
- Emily R. Hankosky (ORCID: https://orcid.org/0000-0001-9934-584X)
- Ivan Houisse
- Martina S. Harris
- Jay Bae (ORCID: https://orcid.org/0000-0002-2322-1450)
- Kristen A. Deger
- Sonja Sorensen
- Madhumita Murphy
- Hong Kan
Institutions
- Ithaka Harbors (US)
- University of North Carolina Wilmington (US)
- Eli Lilly (United States) (US)
Publication Details
- Journal
- Obesity
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1002/oby.24310
- Citations
- 3
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 9.39
Funders
- Eli Lilly and Company